Business Segment, Geographic, and Concentration Risk Information

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Business Segment, Geographic, and Concentration Risk Information

18. BUSINESS SEGMENT, GEOGRAPHIC, AND CONCENTRATION RISK INFORMATION

The Company has two operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue. Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. Consequently, the Company has concluded each operating segment to be a reportable segment. The Company’s operating segments are as follows:

Oncology Innovation Platform— This operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. It focuses specifically on Cell Therapy and Orascovery research platforms. This segment operates in the U.S., Hong Kong, the United Kingdom, and Latin America.

Commercial Platform— This operating segment includes APD, which focuses on the distribution, and sales of specialty pharmaceuticals. This segment provides services and products to external customers based mainly in the U.S.

The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the U.S., Hong Kong, the United Kingdom, and Latin America. The Commercial Platform segment operates and holds long-lived assets located in the U.S. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer.

Segment information is as follows (in thousands):

	Year Ended December 31,
	2022		2021
Total revenue:
Oncology Innovation Platform	$	14,844	$	28,377
Commercial Platform		87,977		66,992
Total consolidated revenue	$	102,821	$	95,369

	Year Ended December 31,
	2022		2021
Total revenue by product group:
Commercial product sales	$	87,977	$	66,993
License fees		11,910		26,832
Contract manufacturing revenue		2,906		1,512
Other revenue		28		32
Total consolidated revenue	$	102,821	$	95,369

	Year Ended December 31,
	2022			2021
Net loss attributable to Athenex, Inc.:
Oncology Innovation Platform	$	(96,670	)	$	(122,704	)
Commercial Platform		(1,309	)		(35,382	)
Segment total		(97,979	)		(158,086	)
Discontinued operations		(5,448	)		(41,682	)
Total consolidated net loss attributable to Athenex, Inc.	$	(103,427	)	$	(199,768	)

	Year Ended December 31,
	2022		2021
Total depreciation and amortization
Oncology Innovation Platform	$	1,064	$	1,317
Commercial Platform		1,258		1,821
Segment total		2,322		3,138
Discontinued operations		2,146		1,865
Total depreciation and amortization	$	4,468	$	5,003

	December 31,
	2022		2021
Total assets:
Oncology Innovation Platform	$	120,206	$	141,808
Commercial Platform		76,541		53,112
Segment total		196,747		194,920
Discontinued operations		7,308		72,528
Total assets	$	204,055	$	267,448

	Year Ended December 31,
	2022		2021
Total revenue
United States	$	96,076	$	89,198
Spain		4,735		5,289
Other foreign countries		2,010		882
Total consolidated revenue	$	102,821	$	95,369

Customer revenue and accounts receivable concentration amounted to the following for the identified periods:

	Year Ended December 31,
	2022			2021
Percentage of total revenue by customer:
Customer A		23	%		20	%
Customer B		20	%		22	%
Customer C		20	%		20	%
Customer D		10	%		29	%

	December 31,
	2022			2021
Percentage of total accounts receivable by customer:
Customer A		34	%		34	%
Customer B		23	%		41	%
Customer C		13	%		3	%